Immunicum secures new financing
Immunicum raises 6 000 000 SEK in new capital in an oversubscribed new share issue to cover expenses for the preparations of an upcoming clinical phase I/II trial on renal cancer.
Notice: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4805